View Older Stories View More Recent Stories
-
Humana (HUM) Tops Q2 EPS by 38c, Beats on Revenue
-
Humana seen posting stronger Q2 as Medicare Advantage margins improve
-
Humana (HUM) PT Raised to $410 at BofA Securities
-
Humana (HUM) call put ratio 1.5 calls to 1 put as share price up 3.7%
-
Humana (HUM) PT Raised to $300 at Cantor Fitzgerald as Q/Q Enrollment Grows
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald: Positive on Medicaid Exposure
-
UBS Reiterates Neutral Rating on Humana (HUM) as Guidance Reaffirmed
-
UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald on $30B RFP Medicaid Award
-
Humana to sell minority stake in Gentiva for $900 million
-
RBC Capital on Humana (HUM): 'We are incrementally more confident in the company's medical cost trends'
-
Humana reaffirms FY 2026 earnings guidance of at least $9 adjusted EPS
-
Deutsche Bank Upgrades Humana (HUM) to Buy
-
Humana completes $1.5 billion pre-capitalized trust securities offering
-
Wolfe says Elevance Health has most conservative Medicaid enrollment guidance
-
Humana commits over $1 million to Louisiana health initiatives
-
Humana (HUM) PT Raised to $254 at Piper Sandler
-
Humana (HUM) PT Raised to $288 at Bernstein SocGen Group
-
Humana (HUM) PT Raised to $269 at Guggenheim
-
Humana (HUM) PT Raised to $262 at UBS
-
Humana (HUM) PT Raised to $267 at BofA Securities
-
Humana (HUM) PT Raised to $246 at RBC Capital
-
Humana (HUM) PT Raised to $250 at Evercore ISI
-
Humana (HUM) PT Raised to $290 at Mizuho
-
Bernstein SocGen Group Reiterates Outperform Rating on Humana (HUM) after earnings
-
Humana (HUM) Tops Q1 EPS by 11c; reaffirms guidance
-
Humana earnings preview Q1: softer profit expected amid Medicare costs
-
Evercore ISI on Humana (HUM): CenterWell partnership with Cuban Cost Plus offers 'some modest benefit'
-
CenterWell Pharmacy partners with Mark Cuban Cost Plus Drug Company
-
Wolfe Research sees managed care companies underearning targets by up to 400%
-
UnitedHealth Group (UNH) Reiterated at Overweight by Cantor Fitzgerald Amid Trough Margins
-
Humana (HUM) PT Lowered to $258 at Mizuho
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald Amid Margin Concerns
-
Humana (HUM) call put ratio 1 call to 1.6 puts into health insurers Medicare rate hike
-
Humana shares surge 12% on 2027 Medicare rate boost; UNH, CVS Rally
-
Humana (HUM), UnitedHealth Group (UNH) Spike: Medicare Finalizes 2.48% Rate Hike For Private Insurers In 2027
-
These 12 stocks have the highest activist attractiveness scores
-
Humana (HUM) PT Lowered to $211 at Bernstein; '2026 guidance is much lower than we expected'
-
Humana (HUM) PT Lowered to $211 at Bernstein SocGen Group
-
Humana (HUM) PT Lowered to $182 at Piper Sandler
-
Humana completes $1 billion junior subordinated notes offering
-
Humana reaffirms 2026 earnings guidance ahead of investor meetings
-
UBS Reiterates Neutral Rating on Humana (HUM)
-
Humana (HUM) PT Lowered to $176 at Barclays
-
Humana commits $1.7 million for Illinois health programs
-
Humana (HUM) PT Lowered to $201 at Cantor Fitzgerald as Stock to Be Range-Bound till Q2
-
RBC Capital Downgrades Humana (HUM) to Sector Perform
-
Humana (HUM) PT Lowered to $252 at Guggenheim
-
Humana (HUM) PT Lowered to $180 at Evercore ISI
-
Humana shares fall as 2026 earnings guidance disappoints investors
